Table of Contents PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY CELL TYPE • Overview • Comparison by cell type • Adult stem cells • Umbilical cord blood stem cells • Embryonic stem cells • Market opportunity by cell type PART 08: CUSTOMER LANDSCAPE PART 09: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Stem cell banking market in Americas • Stem cell banking market in EMEA • Stem cell banking market in APAC • Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS • Increasing implementation of inorganic growth strategies • Rising demand for personalized medicines • Growing acceptance of stem cell therapies PART 13: VENDOR LANDSCAPE • Competitive scenario PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AMAG Pharmaceuticals • Cordlife • Cryo-Cell International • Esperite • Other prominent vendors PART 15: APPENDIX • List of abbreviations List of Exhibits Exhibit 01: Global stem cell banking market: Related market Exhibit 02: Global stem cell banking market: Market characteristics Exhibit 03: Global stem cell banking market: Market segments Exhibit 04: Market definition: Inclusions and exclusions checklist Exhibit 05: Global stem cell banking market: Market size 2017 Exhibit 06: Validation techniques employed for market sizing 2017 Exhibit 07: Global stem cell banking market: Market size and forecast 2017-2022 ($ billions) Exhibit 08: Global stem cell banking market: Year-over-year growth 2017-2022 (%) Exhibit 09: Five forces analysis 2017 Exhibit 10: Five forces analysis 2022 Exhibit 11: Bargaining power of suppliers Exhibit 12: Threat of new entrants Exhibit 13: Threat of substitutes Exhibit 14: Threat of rivalry Exhibit 15: Market condition: Five forces 2017 Exhibit 16: Market condition: Five forces 2022 Exhibit 17: Global stem cell banking market: Segmentation by cell type 2017-2022 (% share) Exhibit 18: Global stem cell banking market: Comparison by cell type Exhibit 19: Global adult stem cell banking market 2017-2022 ($ billions) Exhibit 20: Global adult stem cell banking market: Year-over-year growth 2018-2022 (%) Exhibit 21: Global umbilical cord blood stem cell banking market 2017-2022 ($ billions) Exhibit 22: Global umbilical cord blood stem cell banking market: Year-over-year growth 2018-2022 (%) Exhibit 23: Global embryonic stem cell banking market 2017-2022 ($ billions) Exhibit 24: Global embryonic stem cell banking market: Year-over-year growth 2018-2022 (%) Exhibit 25: Global stem cell banking market: Market opportunity by cell type Exhibit 26: Global stem cell banking market: Customer landscape Exhibit 27: Global stem cell banking market: Segmentation by geography 2017-2022 (% share) Exhibit 28: Regional comparison Exhibit 29: Stem cell banking market in Americas 2017-2022 ($ billions) Exhibit 30: Stem cell banking market in Americas: Year-over-year growth 2018-2022 (%) Exhibit 31: Top three countries in Americas Exhibit 32: Stem cell banking market in EMEA 2017-2022 ($ billions) Exhibit 33: Stem cell banking market in EMEA: Year-over-year growth 2018-2022 (%) Exhibit 34: Top three countries in EMEA Exhibit 35: Stem cell banking market in APAC 2017-2022 ($ billions) Exhibit 36: Stem cell banking market in APAC: Year-over-year growth 2018-2022 (%) Exhibit 37: Top three countries in APAC Exhibit 38: Cancer severity across EU in 2013 and cancer incidence in US in 2014 Exhibit 39: Year-over-Year growth and growth rate of stem cell research spending in US 2013-2016 ($ billions) Exhibit 40: CIRM funding in stem cell research 2014 ($ billions) Exhibit 41: CIRM active programs 2014 Exhibit 42: EC funding for regenerative medicine Exhibit 43: Strategic success factors of vendors in market Exhibit 44: Vendor classification Exhibit 45: Market positioning of vendors Exhibit 46: AMAG Pharmaceuticals: Overview Exhibit 47: AMAG Pharmaceuticals: Business segments Exhibit 48: AMAG Pharmaceuticals: Organizational developments Exhibit 49: AMAG Pharmaceuticals: Geographic focus Exhibit 50: AMAG Pharmaceuticals: Segment focus Exhibit 51: AMAG Pharmaceuticals: Key offerings Exhibit 52: Cordlife: Overview Exhibit 53: Cordlife: Business segments Exhibit 54: Cordlife: Organizational developments Exhibit 55: Cordlife: Geographic focus Exhibit 56: Cordlife: Segment focus Exhibit 57: Cordlife: Key offerings Exhibit 58: Cryo-Cell International: Overview Exhibit 59: Cryo-Cell International: Business segments Exhibit 60: Cryo-Cell International: Organizational developments Exhibit 61: Cryo-Cell International: Geographic focus Exhibit 62: Cryo-Cell International: Segment focus Exhibit 63: Cryo-Cell International: Key offerings Exhibit 64: Esperite: Overview Exhibit 65: Esperite: Business segments Exhibit 66: Esperite: Organizational developments Exhibit 67: Esperite: Geographic focus Exhibit 68: Esperite: Segment focus Exhibit 69: Esperite: Key offerings

AMAG Pharmaceuticals, Cordlife, Cryo-Cell International, Esperite, Cellular Dynamics International, China Cord Blood Corporation, Cordvida, Cryo Stemcell, Cryoviva India, Cytori Therapeutics, Lifecell, PerkinElmer, Reelabs, Smart Cells International, Stemade Biotech, and StemCyte.